Intratumoral HPV16-specific T cells constitute a type I–oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer

Clinical Cancer Research

Volumn 24, Issue 3, 2018, Pages 634-647

  Welters, Marij J P ^a   Ma, Wenbo ^a   Santegoets, Saskia J A M ^a   Goedemans, Renske ^a   Ehsan, Ilina ^a   Jordanova, Ekaterina S ^a   Van Ham, Vanessa J ^a   Van Unen, Vincent ^a   Koning, Frits ^a   Van Egmond, Sylvia I ^a   Charoentong, Pornpimol ^b   Trajanoski, Zlatko ^b   Van Der Velden, Lilly Ann ^a   Van Der Burg, Sjoerd H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD103 ANTIGEN; CD161 ANTIGEN; CISPLATIN; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MACROPHAGE; MAJOR CLINICAL STUDY; MYCOPLASMA; NONHUMAN; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA CELL LINE; OROPHARYNX SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

EID: 85041623527     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-2140     Document Type: Article

References (50)

1. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol 2015;33:3235–42.
2. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24–35.
3. Wansom D, Light E, Worden F, Prince M, Urba S, Chepeha DB, et al. Correlationofcellularimmunitywithhumanpapillomavirus16statusand outcome in patients with advanced oropharyngeal cancer. Arch Otolar-yngol Head Neck Surg 2010;136:1267–73.
4. Thurlow JK, Pena Murillo CL, Hunter KD, Buffa FM, Patiar S, Betts G, et al. Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. J Clin Oncol 2010;28: 2881–8.
5. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, et al. Prognostic value of tumor-infiltrating CD4þ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12:465–72.
6. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128–38.
7. Heusinkveld M, Goedemans R, Briet RJ, Gelderblom H, Nortier JW, Gorter A, et al. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer 2012;131: E74–85.
8. Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003;63:636–41.
9. Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med 2016; 8:334ra52.
10. Punt S, Dronkers EA, Welters MJ, Goedemans R, Koljenovic S, Bloemena E, et al. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(þ) cell frequency. Cancer Immunol Immunother 2016;65:393–403.
11. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadh-doebe TH, Gorter A, Welters MJ, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4þ Th1 cells. J Immunol 2011; 187:1157–65.
12. van Poelgeest MI, Visconti VV, Aghai Z, van Ham VJ, Heusinkveld M, Zandvliet ML, et al. Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer. Cancer Immunol Immunother 2016;65:1451–63.
13. Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Ann Oncol 2015; 26:2141–9.
14. Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, Jha V, et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res 2013;73:2480–92.
15. Ma W, Tummers B, van Esch EM, Goedemans R, Melief CJ, Meyers C, et al. Human papillomavirus downregulates the expression of IFITM1 and RIPK3 to escape from IFNgamma- and TNFalpha-mediated antiproliferative effects and necroptosis. Front Immunol 2016;7:496.
16. van Unen V, Li N, Molendijk I, Temurhan M, Hollt T, van der Meulen-de Jong AE, et al. Mass Cytometry of the Human Mucosal Immune System Identifies Tissue- and Disease-Associated Immune Subsets. Immunity 2016;44:1227–39.
17. Cristofanon S, Abhari BA, Krueger M, Tchoghandjian A, Momma S, Calaminus C, et al. Identification of RIP1 as a critical mediator of Smac mimetic-mediated sensitization of glioblastoma cells for Drozitumab-induced apoptosis. Cell Death Dis 2015;6:e1724.
18. Siegmund D, Kums J, Ehrenschwender M, Wajant H. Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis. Cell Death Dis 2016;7:e2375.
19. Opel D, Schnaiter A, Dodier D, Jovanovic M, Gerhardinger A, Idler I, et al. Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia. Int J Cancer 2015;137:2959–70.
20. vonKnebelDoeberitzM.Newmarkersforcervicaldysplasiatovisualisethe genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229–42.
21. Geng Y, Savage SM, Razani-Boroujerdi S, Sopori ML. Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy. J Immunol 1996;156:2384–90.
22. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(þ) T lymphocyte mobilization to virus-infected tissue requires CD4(þ) T-cell help. Nature 2009; 462:510–3.
23. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189:753–6.
24. Holzinger D, Schmitt M, Dyckhoff G, Benner A, Pawlita M, Bosch FX. Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res 2012;72: 4993–5003.
25. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576–82.
26. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophe-notype relationships and predictors of response to checkpoint blockade. Cell Rep 2017;18:248–62.
27. Tang AL, Hauff SJ, Owen JH, Graham MP, Czerwinski MJ, Park JJ, et al. UM-SCC-104: a new human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoma cell line. Head Neck 2012;34:1480–91.
28. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, et al. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 2010;32:417–26.
29. Becht E, Giraldo NA, Germain C, de Reynies A, Laurent-Puig P, Zucman-Rossi J, et al. Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv Immunol 2016;130:95–190.
30. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494:361–5.
31. van der Sluis TC, van Duikeren S, Huppelschoten S, Jordanova ES, Beyr-anvand Nejad E, Sloots A, et al. Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death. Clin Cancer Res 2015;21:781–94.
32. Yang G, Xu Y, Chen X, Hu G. IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene 2007;26:594–603.
33. Wu CC, Tsai FM, Shyu RY, Tsai YM, Wang CH, Jiang SY. G protein-coupled receptor kinase 5 mediates Tazarotene-induced gene 1-induced growth suppression of human colon cancer cells. BMC Cancer 2011;11:175.
34. Kang YH, Seigel B, Bengsch B, Fleming VM, Billerbeck E, Simmons R, et al. CD161(þ)CD4(þ) T cells are enriched in the liver during chronic hepatitis and associated with co-secretion of IL-22 and IFN-gamma. Front Immunol 2012;3:346.
35. Ramos CA, Narala N, Vyas GM, Leen AM, Gerdemann U, Sturgis EM, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother 2013;36:66–76.
36. Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4þ T cells in human melanoma. Nat Med 2015; 21:81–5.
37. Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood 2013;121:2402–14.
38. Balermpas P, Rodel F, Rodel C, Krause M, Linge A, Lohaus F, et al. CD8þ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). Int J Cancer 2016;138:171–81.
39. Kindt N, Descamps G, Seminerio I, Bellier J, Lechien JR, Pottier C, et al. Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas. Oral Oncol 2016; 62:1–10.
40. Rajjoub S, Basha SR, Einhorn E, Cohen MC, Marvel DM, Sewell DA. Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J 2007;86:506–11.
41. Wang ZQ, Milne K, Derocher H, Webb JR, Nelson BH, Watson PH. CD103 and intratumoral immune response in breast cancer. Clin Cancer Res 2016;22:6290–7.
42. Takahashi T, Dejbakhsh-Jones S, Strober S. Expression of CD161 (NKR-P1A) defines subsets of human CD4 and CD8 T cells with different functional activities. J Immunol 2006;176:211–6.
43. Majchrzak K, Nelson MH, Bailey SR, Bowers JS, Yu XZ, Rubinstein MP, et al. Exploiting IL-17-producing CD4þ and CD8þ T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother 2016;65: 247–59.
44. Iliopoulou EG, Karamouzis MV, Missitzis I, Ardavanis A, Sotiriadou NN, Baxevanis CN, et al. Increased frequency of CD4þ cells expressing CD161 in cancer patients. Clin Cancer Res 2006;12: 6901–9.
45. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015;21:938–45.
46. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. meta-analysis of chemotherapy on head and neck cancer. Lancet 2000; 355:949–55.
47. Hoek J, Bloemendal KM, van der Velden LA, van Diessen JN, van Wer-khoven E, Klop WM, et al. Nephrotoxicity as a dose-limiting factor in a high-dose cisplatin-based chemoradiotherapy regimen for head and neck carcinomas. Cancers 2016;8:pii:E21.
48. Rades D, Fehlauer F, Sheikh-Sarraf M, Kazic N, Basic H, Poorter R, et al. Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer. Head Neck 2008;30:235–41.
49. Blank CU, Haanen JB, Ribas A, Schumacher TN. CANCER IMMUNOLOGY. The "cancer immunogram". Science 2016;352:658–60.
50. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013;73:1733–41.